Vir Biotechnology (NASDAQ: VIR) net income
Vir Biotechnology reported a net loss of $438.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $522.0m. Earnings per share were −$3.16.
Vir Biotechnology's best year of the last 8 was fiscal 2021. The biggest drop was in fiscal 2022, −2.4%. It reported a loss in 6 of those 8 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$438.0m | — | −638.9% | −$3.16 |
| 2024 | −$522.0m | — | −703.4% | −$3.83 |
| 2023 | −$615.1m | −219.2% | −713.7% | −$4.59 |
| 2022 | $515.8m | −2.4% | 31.9% | $3.89 |
| 2021 | $528.6m | — | 48.3% | $4.07 |
| 2020 | −$298.7m | — | −391.1% | −$2.51 |
| 2019 | −$174.7m | — | −2,159.0% | −$5.76 |
| 2018 | −$115.9m | — | −1,086.3% | — |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Vir Biotechnology net income compared with its sector
By net income for its latest fiscal year, Vir Biotechnology ranks 470th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Vir Biotechnology, −638.9%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 468th | Agios Pharmaceuticals | −$412.8m | −764.0% |
| 469th | Guardant Health | −$416.3m | −42.4% |
| 470th | Vir Biotechnology | −$438.0m | −638.9% |
| 471st | Oscar Health | −$443.2m | −3.8% |
| 472nd | Dyne Therapeutics | −$446.2m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Vir Biotechnology
- How much did Vir Biotechnology earn in fiscal 2025?
- Vir Biotechnology reported a net loss of $438.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $522.0m.
- What are the earnings per share of Vir Biotechnology?
- They were −$3.16 in fiscal 2025, compared with −$3.83 in fiscal 2024.
- What was the most profitable year for Vir Biotechnology?
- Of its last 8 fiscal years, fiscal 2021, with $528.6m.
- Where does Vir Biotechnology rank in its sector by net income?
- It ranks 470th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Vir Biotechnology come from?
- From the annual report (Form 10-K) that Vir Biotechnology files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Vir Biotechnology files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018. More on Vir Biotechnology: the Vir Biotechnology page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.